

## DECREASE ON 2018 RESULTS

Longjumeau, November 21<sup>st</sup>, 2018

**PCAS (Euronext Paris: PCA)**, a specialist in developing and producing complex molecules for life sciences and innovative technologies, communicates today on its activity and results expected for 2018.

On 7<sup>th</sup> November 2018, we announced that:

- The Group's net sales for 2018 were expected to be close to 2017 level;
- Operational difficulties had been faced over the last 2 months, reducing some plants' production capacities; and that, as a consequence, the Group's results could be significantly affected should these issues continue during the last months of 2018, given the high level of activity towards the end of the year or if the American currency were to weaken against the euro.

Operational difficulties are still on going, in particular at one production plant of the Group. The Group's net sales and results 2018 will be below 2017 levels.

All of the Group's teams are heavily involved to ensure that the financial impacts will be as limited as possible.



### NEXT FINANCIAL DISCLOSURE:

*2018 Results on Wednesday, February 20, 2019*

#### ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: [www.pcas.com](http://www.pcas.com)

PCAS

Newcap

Vincent Touraille / Eric Moissenot  
PCAS

Emmanuel Huynh / Louis-Victor Delouvrier  
NewCap  
Communication financière et Relations Investisseurs

PCA  
LISTED  
EURONEXT

Tél. : +33 1 69 79 61 32  
[www.pcas.com](http://www.pcas.com)

Tél. : +33 1 44 71 98 53  
[pcas@newcap.eu](mailto:pcas@newcap.eu)